Currently out of the existing stock ratings of Timothy Chiang, 63 are a BUY (92.65%), 3 are a HOLD (4.41%), 2 are a SELL (2.94%).

Timothy Chiang

Work Performance Price Targets & Ratings Chart

Analyst Timothy Chiang, currently employed at CAPITAL ONE, carries an average stock price target met ratio of 34.24% that have a potential upside of 15.27% achieved within 190 days.

Timothy Chiang’s has documented 168 price targets and ratings displayed on 13 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on IRWD, Ironwood Pharmaceuticals at 01-Sep-2022.

Wall Street Analyst Timothy Chiang

Analyst best performing recommendations are on SRPT (SAREPTA THERAPEUTICS).
The best stock recommendation documented was for SRPT (SAREPTA THERAPEUTICS) at 6/15/2018. The price target of $120 was fulfilled within 4 days with a profit of $17.71 (17.31%) receiving and performance score of 43.28.

Average potential price target upside

of $17.01 (13.96%) on SRPT (SAREPTA THERAPEUTICS).
of $12.38 (77.56%) on IDYA (IDEAYA BIOSCIENCES).
of $8.56 (17.75%) on PCRX (PACIRA PHARMACEUTICALS).

AMPH Amphastar P EYEN Eyenovia IRWD Ironwood Pharmaceuticals MYL Viatris RLYP Relypsa SGYP Synergy Pharmaceuticals SRPT Sarepta Therapeutics TEVA Teva Pharma Industries Ltd ADR VTRS Viatris IDYA Ideaya Biosciences AMRX Amneal Pharmaceuticals, Common Stock ARDX Ardelyx CDTX Cidara Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Jason Gerberry (BAML)